Previous Article | Next Article 
Journal of Virology, September 2000, p. 8550-8557, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
CD4-Negative Cells Bind Human Immunodeficiency
Virus Type 1 and Efficiently Transfer Virus to T Cells
Gene G.
Olinger,
Mohammed
Saifuddin, and
Gregory T.
Spear*
Department of Immunology/Microbiology, Rush
University, Chicago, Illinois 60612
Received 22 February 2000/Accepted 21 June 2000
 |
ABSTRACT |
The ability of human immunodeficiency virus strain MN
(HIVMN), a T-cell line-adapted strain of HIV, and X4 and R5
primary isolates to bind to various cell types was investigated. In
general, HIVMN bound to cells at higher levels than did the
primary isolates. Virus bound to both CD4-positive (CD4+)
and CD4-negative (CD4
) cells, including neutrophils, Raji
cells, tonsil mononuclear cells, erythrocytes, platelets, and
peripheral blood mononuclear cells (PBMC), although virus bound at
significantly higher levels to PBMC. However, there was no difference
in the amount of HIV that bound to CD4-enriched or CD4-depleted PBMC.
Virus bound to CD4
cells was up to 17 times more
infectious for T cells in cocultures than was the same amount of
cell-free virus. Virus bound to nucleated cells was significantly more
infectious than virus bound to erythrocytes or platelets. The enhanced
infection of T cells by virus bound to CD4
cells was not
due to stimulatory signals provided by CD4
cells or
infection of CD4
cells. However, anti-CD18 antibody
substantially reduced the enhanced virus replication in T cells,
suggesting that virus that bound to the surface of CD4
cells is efficiently passed to CD4+ T cells during
cell-cell adhesion. These studies show that HIV binds at relatively
high levels to CD4
cells and, once bound, is highly
infectious for T cells. This suggests that virus binding to the surface
of CD4
cells is an important route for infection of T
cells in vivo.
 |
INTRODUCTION |
Human immunodeficiency virus type 1 (HIV-1) is known to infect T cells by a sequence of events including
binding of gp120 to CD4 and chemokine receptors, membrane fusion,
reverse transcription, and integration. Four forms of infectious virus
particles have been shown to be present in vivo, and all could be
important for infection of CD4+ target cells. These forms
include cell-associated virus, cell-free virus, immune-complexed virus,
and cell-bound virus. During HIV replication, progeny virions assemble
and bud from the surface of infected cells. The assembling and budding
virus on the surface of infected cells is generally referred to as
cell-associated virus and has been shown to be highly infectious to
neighboring target cells (2, 33). Transmission of
cell-associated virus to target cells can be >100 times more efficient
than that of cell-free virus (2, 4). Virus released from
infected cells is considered cell free and can reach high levels
(>106 RNA copies/ml) in blood (6). The
cell-free virus half-life in plasma is less than 110 min, but the exact
turnover mechanism(s) remains poorly understood (31).
Several studies have shown that a portion of the cell-free virus exists
as immune complexes (HIV IC) resulting from binding of specific
antibody and/or complement deposition on the virion surface (7,
22, 24, 36, 37).
HIV may also bind to CD4-negative (CD4
) cells in vivo,
which we refer to as cell-bound virus. While binding of HIV to
CD4
cells has been studied less than virus binding to
CD4-positive (CD4+) cells, several CD4
cell
lines and primary cell types have been shown to bind HIV even though
they do not become infected. Mondor et al. demonstrated that the amount
of HIV binding to CD4
HeLa cells was equivalent to that
of virus binding to HeLa cells that express high levels of CD4
(23). Fujiwara et al. demonstrated that isolated follicular
dendritic cells (FDC) capture HIV that is not in immune complexes but
do not become infected (11). Erythrocytes from some
individuals are reported to bind HIV through the Duffy antigen receptor
for chemokines (19). Binding of HIV to CD4
cells could have functional consequences such as induction of signals
in cells or induction of apoptosis. Also, since most CD4
cells do not support virus replication, some have speculated that HIV
binding to uninfectable cells could provide a mechanism for clearance
of virus from circulation (23). Alternatively, several
studies have demonstrated that virus bound to the surface of cells
remains infectious for T cells. Thus, HIV IC bound to FDC can infect T
cells (11) even in the presence of neutralizing antibody
(13). A non-syncytium-inducing strain of HIV bound to
erythrocytes through the Duffy antigen receptor for chemokines was
shown to infect peripheral blood mononuclear cells (PBMC) (19). Infection of T cells with HIV IC bound to B cells was 10- to 100-fold more efficient than cell-free virus infection of T
cells (15, 16). The mechanism of infection of T cells by
virus bound to CD4
cells may vary depending on the cell
type but could represent an important pathway of HIV infection in vivo.
The goal of the current study was to determine if HIV binds to
CD4
primary cells and cell lines. Furthermore, we
determined if virus bound to CD4
cells can infect
CD4+ T lymphocytes and investigated the mechanism of infection.
 |
MATERIALS AND METHODS |
Cell lines and isolation of primary cells.
The T-lymphocytic
H9 (HTB-176) and B-lymphocytic Raji (CCL-86) cell lines used were
obtained from the American Type Culture Collection (ATCC; Manassas,
Va.). Cells were grown in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal bovine serum (Whittaker M. A. Bioproducts,
Walkersville, Md.) and gentamicin (Sigma, St. Louis, Mo.) at 50 µg/ml. Antibodies to leukocyte function-associated antigen type 1
(LFA-1
; CD18) and CD14 were obtained from the TS1/18.1.2.11
hybridoma (HB-203; ATCC) and the 261C hybridoma (HB-246; ATCC),
respectively. Each antibody was purified using an Affinity Pak
Immobilized Protein A column (Pierce, Rockford, Ill.).
PBMC obtained from healthy donors were isolated by Ficoll-Hypaque
gradient centrifugation (Whittaker M. A. Bioproducts). Stimulated PBMC were produced by culture in medium containing phytohemagglutinin (PHA; 3.0 µg/ml) for 2 days, followed by culture in medium containing interleukin-2 at 20 U/ml. Human recombinant interleukin-2 was obtained
through the AIDS Research and Reference Reagent Program, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, from Maurice Gately, Hoffman-La Roche, Inc. (20).
Erythrocytes were collected from the bottom layer of the density
gradients and washed twice with phosphate-buffered saline.
Neutrophils were isolated from healthy donors by Ficoll-Hypaque
centrifugation. The bottom layer was collected, and erythrocytes
were
lysed by three treatments with ice-cold deionized water,
followed by
treatment with 2× Hanks balanced salt solution containing
5 mM HEPES
buffer (Gibco BRL, Grand Island, N.Y.). To isolate
platelets, blood was
drawn in acid-citrate-phosphate-dextrose
anticoagulant (Biowhittaker)
and centrifuged at 400 ×
g. The plasma
fraction
containing platelets was centrifuged (800 ×
g), washed
twice with acid-citrate-phosphate-dextrose in 0.85% NaCl solution
(1:6, vol/vol), and resuspended in 0.85% NaCl until use, when
the
platelets were resuspended in complete
medium.
Fresh tonsil tissues were obtained from the Pathology Department of
Rush Medical Center. Tonsil mononuclear cells were isolated
by teasing
the tissues. Cells were washed and passed through a
70-µm nylon
Spectra/Mesh filter (Spectrum Medical Industry, Inc.,
Houston, Tex.) to
remove aggregated
cells.
CD4
+ T cells were positively isolated from fresh PBMC using
anti-CD4 antibody-conjugated Dynabeads M-450 and CD4/CD8 DETACHaBEAD
(Dynal, Oslo, Norway) in accordance with the manufacturer's protocols.
After an additional positive selection of CD4
+ T cells, the
remaining cells were used as CD4

PBMC. The composition of
the CD4
+ and CD4

cell population as measured
by flow cytometry, was >99% CD4
+ and <1%
CD4
+ (data not
shown).
Virus stocks.
T-cell line-adapted (TCLA) HIV-1 strain MN
(HIV-1MN; AIDS Research and Reference Reagent Program [no.
317], contributed by Robert Gallo) was grown in H9 cells. The 8E5/LAV
cell line (AIDS Research and Reference Reagent Program [no. 95],
contributed by Thomas Folks) was used to derive reverse
transcriptase-defective virus and DNA for PCR standards (8).
The primary isolates of HIV (HIVGP [X4] and
HIVTH [R5]) were produced in PHA-stimulated PBMC as
previously described (38).
Binding of HIV to cells.
To measure binding of HIV to cells,
a pellet of 5 × 106 erythrocytes or platelets or
1 × 106 Raji cells, neutrophils, total PBMC,
CD4-depleted PBMC, purified CD4+ T cells, or tonsil
mononuclear cells was incubated with 50 µl of virus containing
approximately 1,000 pg of p24 for 2 h on ice. Cells were washed to
remove unbound virus and transferred to fresh tubes since some virus
binding to tubes occurred during incubation. Pelleted cells were
treated with 0.5% Triton X-100, and the amount of virus bound to cells
was detected by p24 antigen enzyme-linked immunosorbent assay (ELISA;
National Institutes of Health AIDS Vaccine Program, Frederick, Md.). To
protect neutrophil-bound HIV-1 p24 from proteolytic degradation, the
protease inhibitors leupeptin (2 µg/ml), aprotinin (10 µg/ml), and
phenylmethylsulfonyl fluoride (2 mM; Sigma) were added to the Triton
X-100 solution. Tonsil-derived cells and PBMC were gamma irradiated
with 5,000 rads before being used in HIV binding and replication experiments.
For some virus binding experiments, pelleted Raji cells were first
fixed in a 0.5% formaldehyde solution for 10 min at room
temperature.
Cells were washed four times with serum-free medium,
resuspended in
complete medium, and then incubated with
virus.
Infection of T cells by cell-bound and cell-free HIV.
Washed
cells with bound virus (see above) or dilutions of cell-free virus were
added to cultures of 2.5 × 105 H9 cells or
PHA-stimulated PBMC in round-bottom polypropylene tubes (12 by 75 mm;
Becton Dickinson, Franklin Lakes, N.J.). After 12 h, the cells
were washed and cultured in 48-well cell culture plates (Corning Inc.,
Corning, N.Y.) for an additional 6 days and collected on day 7. The
total volume for all experiments was 500 µl. HIV-1 replication was
assessed by measuring the p24 antigen in culture supernatants. In some
experiments, to assess the effects of adhesion molecules on HIV
replication, anti-LFA-1
or anti-CD14 antibody was added at 1 µg/ml
to H9 cells or PHA-stimulated PBMC 20 min prior to coculture with
cell-bound virus. Antibody was maintained at 1 µg/ml throughout the coculture.
PCR amplification of HIV-1 DNA.
Cells in cultures containing
Raji cells with bound virus, H9 cells infected with cell-free virus, or
H9 cells infected with Raji-bound virus were pelleted and washed.
Genomic DNA was isolated using DNAzol (Molecular Research Center, Inc.,
Cincinnati, Ohio). DNA from approximately 40,000 cells (10 µl) was
amplified by PCR using primers SK38 (forward, 5'-ATA ATC CAC CTA TCC
CAG TAG GAG AAA T-3') and SK39 (reverse, 5'-TTT GGT CCT TGT CTT ATG TCC
AGA ATG C-3') (Integrated DNA Technologies, Inc., Coralville, Iowa), which amplify a 115-bp region of HIV-1 gag DNA (18,
27). DNA dilutions from 8E5/LAV cells were used as standards. The
PCRs were performed in a Perkin-Elmer (Norwalk, Conn.) 2400 automated thermocycler. The total reaction volume was 100 µl and consisted of
1× PCR buffer (200 mM Tris-HCl, 500 mM KCl, pH 9.3) containing final
concentrations of 1.5 mM MgCl2, 0.2 mM deoxynucleoside
triphosphates, 0.5 µM each primer, and 2.5 U of Taq
polymerase (Gibco BRL Life Technologies, Gaithersburg, Md.). The
thermocycle profile consisted of 30 cycles of denaturation at 95°C,
annealing at 55°C, and extension at 72°C (30 s each). In addition,
a 5-min hold denaturing step was added to the beginning and a 5-min
hold extension step was added to the end. Amplified products were
analyzed on a 2% agarose gel (Ultrapure; Gibco BRL Life Technologies).
After ethidium bromide staining, amplified DNA was visualized by UV fluorescence.
 |
RESULTS |
CD4
cells bind HIV-1.
Studies were performed to
determine if TCLA HIVMN or primary isolates of HIV could
bind to CD4
and CD4+ cell lines. The amount
of HIVMN binding to CD4
Raji cells (2.6% of
input, Fig. 1A) was slightly lower but
not significantly different from the amount binding to CD4+
H9 T cells (3.5%; P = 0.32, t test). Primary isolates
of HIV also bound to both Raji and H9 cells (Fig. 1A). The levels of X4
HIVGP and R5 HIVTH binding to Raji and H9 cells
were similar (P = 0.18 for binding to Raji cells and
P = 0.5 for binding to H9 cells, t test),
although the overall binding of primary isolates to these cells was
lower than that of TCLA HIVMN (P = 0.003, t test). Therefore, TCLA HIVMN and primary isolates of HIV
bound to both CD4
Raji B cells and CD4+ H9 T
cells.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
Binding of HIV to cell lines and primary blood cells.
HIVMN or primary isolates of HIV (R5 HIVTH and
X4 HIVGP) were incubated with Raji cells, H9 cells,
neutrophils, freshly isolated or PHA-stimulated PBMC, tonsil
mononuclear cells, erythrocytes (RBC), or platelets (A) or with freshly
isolated PBMC or CD4-enriched or -depleted PBMC (B) for 2 h on
ice. Cells were washed to remove unbound virus and transferred to fresh
tubes. Cells were lysed with Triton X-100, and bound virus was measured
by p24 ELISA. The percentage of virus bound to cells was calculated by
dividing the total amount of virus added into the amount of virus
bound. The values shown indicate the amount of virus bound to
106 cells. The results shown are the mean ± the
standard deviation of at least three experiments for each cell type.
|
|
Binding of HIV to primary cells isolated from peripheral blood and
tonsil tissue was also analyzed. Interestingly, CD4

neutrophils, erythrocytes, and platelets all bound significant
levels
of both TCLA and primary isolates of HIV (Fig.
1A). Tonsil
mononuclear
cells consisting of approximately 60% B lymphocytes
and 40% T
lymphocytes also bound both TCLA and primary isolates
of HIV. The
amount of virus binding to PBMC was greater than that
binding to the
other primary cell types tested (
P < 0.001 for
both
HIV
TH and HIV
GP,
t test). The
percentages of HIV
MN, HIV
TH,
and
HIV
GP binding to PBMC were 7.7, 5.2, and 5.8%,
respectively.
Stimulation of PBMC with PHA for 2 days did not
significantly
change virus binding. The binding of HIV
MN
was consistently higher
than binding of primary isolates for all of the
cells tested (
P < 0.001,
t test). Although primary
isolate binding varied depending
on the cell type, there was no
significant difference between
HIV
GP and HIV
TH
in binding to cells (
P = 0.06, paired
t test).
Since HIV bound at higher levels to PBMC, we determined whether the
CD4-depleted fraction of PBMC could also bind HIV. PBMC
depleted of CD4
cells by magnetic bead separation (99% CD4

) had levels
of virus binding essentially equivalent to those
of purified CD4 cells
(99% CD4
+) or unseparated PBMC (Fig.
1B). These results
indicate that both
TCLA and primary isolates of HIV could bind to cells
independently
of CD4
expression.
Cell-bound HIV efficiently infects T cells during coculture.
Since HIV bound to CD4
cells, we investigated the
possibility that the cell-bound virus could infect CD4+ T
cells. Cell-bound virus was cultured with T cells for 7 days, and
levels of replication were assessed. For comparison, T cells were
infected with several dilutions of cell-free HIV. To determine if
CD4
cells were infected, the cells with bound virus were
also cultured alone. When Raji cells, with 26 pg of p24 of bound virus,
were cocultured with H9 cells, there was marked virus replication, resulting in 1,808 pg of p24/ml (Fig. 2A;
Table 1). No virus replication was
detected in cultures containing only Raji cells with bound
HIVMN. In contrast, infection of H9 cells with the same
concentration of cell-free virus (estimated from the curve generated by
dilutions of cell-free virus) resulted in low HIV replication (<30
pg/ml). In six experiments, an average of 17-fold more virus
replication was observed in H9 cells cultured with Raji cell-bound
virus than in cultures with the same amount of cell-free virus (Table
1). We also estimated that 10-fold more cell-free virus was required to
produce virus replication in H9 cells similar to that observed with
Raji-bound virus infection of H9 cells. These results indicated that
virus bound to Raji cells is highly infectious for H9 T cells.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Infection of T cells by cell-bound and cell-free HIV.
(A) HIVMN was incubated with Raji cells. Cells were washed
and then cultured alone (open circle) or with H9 T cells (filled
circle) for 7 days. H9 cells were also cultured with several dilutions
of cell-free virus (filled triangles). (B) HIVGP (circles)
and HIVTH (squares) primary isolates were incubated with
neutrophils. Cells were washed and then cultured alone (hatched
symbols) or with autologous PHA-stimulated PBMC (open symbols).
Stimulated PBMC were also cultured with dilutions of cell-free viruses
(closed symbols). For both panels A and B, virus replication was
assessed by measuring p24 levels in culture supernatants. The values
shown are the mean ± the standard deviation of three determinates
in one representative experiment. At least three experiments were
performed.
|
|
The ability of neutrophil-bound HIV primary isolates to infect
PHA-stimulated T cells was also tested. Coculture of neutrophil
cell-bound virus (9 pg of HIV
TH or 7 pg of
HIV
GP) with autologous
PHA-stimulated PBMC resulted in HIV
replication of 6,519 and 7,082
pg of p24/ml in culture supernatants
(Fig.
2B; Table
1). No virus
replication was detected in cultures
containing only neutrophils
with bound virus (Fig.
2B). Virus
replication due to neutrophil-bound
HIV
TH and
HIV
GP was nine- and sixfold greater, respectively, than
infection of PBMC with the same amount of cell-free virus (Table
1).
Approximately, 12- and 7-fold more cell-free HIV
TH and
HIV
GP,
respectively, was needed to produce virus
replication similar
to neutrophil-bound virus infection of stimulated
PBMC.
Replication of virus bound to fresh or PHA-stimulated PBMC was also
assessed. Since the PBMC contain CD4
+ cells that could be
infected and contribute to virus replication
in cocultures, the PBMC
were irradiated to suppress infection
of these cells before virus
binding. Coculture of virus bound
to irradiated fresh PBMC with
PHA-stimulated PBMC resulted in
10- and 8-fold higher virus replication
than similar amounts of
cell-free HIV
GP or
HIV
TH, respectively (Table
1). Only background
levels of
virus production were observed in cultures containing
irradiated fresh
PBMC with bound HIV. Virus bound to irradiated
PHA-stimulated PBMC
resulted in nine- and sevenfold higher virus
replication than
similar amounts of cell-free HIV
GP and
HIV
TH,
respectively (Table
1). However, irradiation only
partially prevented
virus replication in stimulated PBMC (Table
1).
Similarly, virus
bound to tonsil mononuclear cells also resulted in 9- and 12-fold
increases in virus replication for HIV
TH and
HIV
GP, respectively
(Table
1). No virus replication was
observed in irradiated tonsil
cells cultured alone with bound
virus.
Lastly, we assessed the ability of erythrocyte- and platelet-bound HIV
to infect stimulated PBMC. Although erythrocyte- and
platelet-bound
virus was able to efficiently infect T cells, the
enhancement over
replication of cell-free virus was only two-
to threefold (Table
1).
Bound HIV does not productively infect CD4
Raji
cells.
Culture of virus bound to CD4
cells with T
cells resulted in marked increases in virus replication over
replication due to cell-free virus. Experiments were performed to
determine the mechanism of the enhanced virus replication. Since some
reports have shown that HIV can infect B cells, we first determined
whether replication of virus in Raji cells contributed to the increased
virus production. Culture of Raji cells with bound virus for 7 days
resulted in only background levels of virus replication (Fig. 2A and
Table 1), indicating little or no infection of Raji cells. Since the assay of p24 in culture supernatants may not have been sensitive enough
to detect low levels of virus infection in Raji cells, we used a
previously described PCR method to detect HIV DNA in cultured Raji
cells (27). While HIV DNA was detected in cocultures of Raji
and H9 cells and in cultures with cell-free infection of H9 cells, no
viral DNA was detected in Raji cells cultured alone with virus (Fig.
3). Since a faint band was observed with 94 copies of integrated viral DNA per 40,000 cells (Fig. 3B), fewer
than 94 Raji cells were infected in cultures containing Raji cells
alone with bound virus. In contrast, 375 to 1,250 HIV DNA copies per
40,000 cells were observed in cultures containing Raji and H9 cells.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 3.
HIV DNA in cells cultured with virus. Raji cells were
incubated with HIVMN, washed, and cultured alone or with H9
cells as described in the legend to Fig. 2. After 7 days, DNA was
isolated and the amount of DNA corresponding to 40,000 cells was PCR
amplified using primers SK38 and SK39 (18, 27). Samples were
run on agarose gels, and bands corresponding to the 115-bp amplified
product were visualized by ethidium bromide staining. (A) HIV-1 DNA
PCR. Images: 1, Raji cells with bound HIVMN cultured with
H9 cells; 2, Raji cells with bound HIVMN cultured alone; 3, H9 cells infected with a large dose of cell-free HIVMN; 4, uninfected H9 cells; 5, Raji cells without virus. (B) Dilutions of
8E5/LAV cell DNA (numbers of HIV-1 DNA copies per 40,000 cells). For
example, the image labeled 10,000 contained 10,000 8E5/LAV cells and
30,000 Raji cells as filler cells.
|
|
Raji cells do not stimulate virus replication in H9 cells.
Another possible explanation for the increased virus replication in
cultures of T cells with virus bound to Raji cells was that Raji cells
may have enhanced virus replication by stimulating infected T cells
through either cell-cell contact or release of soluble factors. To
determine if Raji cells stimulate increased virus replication in H9
cells, H9 cells were infected with HIVMN and then cultured
in the presence or absence of Raji cells. HIV replication in infected
H9 cells was slightly suppressed by addition of Raji cells (Fig.
4A) (2,638 and 2,200 pg of p24/ml,
respectively; P = 0.2, t test). To determine if virus
binding could stimulate Raji cells and, in turn, stimulate virus
expression in infected H9 cells, Raji cells were incubated with
replication-defective HIV derived from 8E5/LAV cells before incubation
with infected H9 cells. There was no increase in virus expression in
the H9 cells when they were cocultured with Raji cells that had
previously bound replication-defective virus (Fig. 4A; P = 0.58, t test).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of Raji cells on virus replication in H9 T cells.
(A) H9 cells were infected by overnight incubation with
HIVMN. The next day, H9 cells were washed and cultured
either alone or with untreated Raji cells or with Raji cells that had
been incubated with noninfectious HIV8E5 and then washed.
(B) Untreated Raji cells and Raji cells fixed with 0.5% formaldehyde
were incubated with HIVMN, washed, and then cocultured with
H9 cells. After 7 days, HIV replication in cultures was determined by
p24 ELISA. In this experiment, 27 pg of p24 bound to unfixed Raji cells
while 22 pg of p24 bound to fixed Raji cells. For comparison, virus
replication levels are shown for H9 cells infected with 30 pg of
cell-free virus. For both panels A and B, the results shown are the
mean ± the standard deviation of replicate samples of one
experiment that is representative of at least two experiments.
|
|
To further demonstrate that Raji cells did not produce virus or
secreted molecules that enhanced HIV replication in H9 cells,
we
metabolically fixed the Raji cells with formaldehyde. We next
bound
virus to fixed Raji cells and subsequently cocultured them
with H9
cells. The amount of virus binding to fixed Raji cells
was similar to
the amount of binding to untreated Raji cells (data
not shown), and the
levels of HIV replication during coculture
were comparable to untreated
Raji cell-bound infection of H9 cells
(Fig.
4B). These results indicate
that it is unlikely that a signal
induced by Raji cells enhances virus
replication in H9
cells.
Raji cells do not selectively bind infectious virus.
Another
possible mechanism that could account for enhanced virus infection in
the coculture system is Raji cell binding of only infection-competent
virus particles. To determine whether Raji cells bind only infectious
virus, we incubated HIVMN with Raji cells to allow virus
binding. Cells were pelleted, and the remaining unbound virus was
successively bound to fresh Raji cells for a total of three cycles.
After each cycle of binding, the cells were washed and the percentage
of bound virus was determined. Each successive round of Raji cell-bound
virus was cocultured with H9 cells to determine the level of virus
replication. Virus binding to Raji cells was similar (2.3, 2.6, and
2.5%) for each exposure of virus to Raji cells. The fold increase in
virus infection due to the first round of bound virus (100%) was
similar to that due to the successive two rounds of Raji-bound virus
(91 and 118%), indicating that selective binding of
infection-competent virus to Raji cells did not occur.
Blocking of cell-cell interactions inhibits cell-bound virus
infection of T cells.
We next determined whether cell-cell
interaction could mediate efficient transfer of virus from
CD4
cells to T cells. Since previous studies showed that
anti-LFA-1 antibody blocked HIV transfer from FDC to T cells, anti-CD18
(LFA-1
) antibody was added to the target T cells before coculture
with virus bound to Raji cells and maintained throughout the culture. At 1 µg/ml, anti-LFA-1 antibody inhibited Raji-bound virus infection of H9 cells by 82% while a control antibody did not affect virus replication significantly (Table 2).
Since incorporation of ICAM in HIV virions has been shown to enhance
virus infectivity (9, 10), we also assessed the effect of
anti-LFA-1 antibody treatment of T cells in cell-free virus infection.
Consistent with previous studies, anti-LFA-1 antibody reduced cell-free
infection of H9 cells, but by only 26% (Table 2). To determine if
cell-cell interactions also contributed to the efficient infection of
primary virus bound to primary cell types, PHA-stimulated PBMC were
treated with anti-LFA-1 antibody before incubation with virus bound to
neutrophils or tonsil mononuclear cells. As shown in Table 2, there was
70 to 93% inhibition of virus replication in PBMC that had been
cultured in the presence of LFA-1 antibody. These experiments indicate that the interaction between cells plays an important role in transfer
of virus from CD4
cells to CD4+ cells.
 |
DISCUSSION |
Our results demonstrate that TCLA HIV-1MN and primary
isolates bind to cells that lack CD4. Although CD4 is considered to be
the receptor for HIV, our data showing that HIV binds to neutrophils, Raji cells, CD4
PBMC, erythrocytes, and platelets
indicate that binding of HIV can be independent of CD4. However, in
CD4+ cells, including T cells, CD4 may be important for
virus binding. For example, Mondor et al. showed that an anti-CD4
monoclonal antibody partially blocked HIV binding to a T-cell line
(23). Receptor-independent binding of virus particles to
cells has been observed for several other viruses, including vesicular
stomatitis virus (34, 35), Rous sarcoma virus (25,
29), and murine leukemia virus (MLV) (30). Studies by
Pizzato et al. (30) showed that early phases of MLV
attachment to cells did not require expression of virus receptors on
the host cell. Furthermore, envelope-defective virus binding to cells
was similar to binding of wild-type MLV. Studies with HIV suggest that
CD4 is not always essential for virus attachment to cells. Mondor et
al. (23) demonstrated that CD4
HeLa cells bind
HIV at levels equivalent to HeLa cells expressing high or moderate
levels of CD4. Studies by Saphire et al. showed that gp120-deficient
HIV particles could bind to CD4+ HeLa cells, suggesting
that the virus envelope proteins were not required for virus attachment
(32). Glycoaminoglycans, specifically, heparan sulfates
(14, 23, 26, 28), virus-incorporated adhesion molecules
(9), and recently cyclophilin A (32), have been
implicated as molecules responsible for the attachment of HIV to cells,
although it is not known if HIV binds to all CD4
cells
through these mechanisms.
The fact that HIV binds to a variety of cell types has significant
implications. The observed binding could contribute to clearance of
virus from plasma, since most of the cells in blood are
CD4
. Virus binding could also lead to CD4-independent
infection, induction of signaling pathways, and even apoptosis. We
compared the infectivity of cell-bound virus with that of cell-free
virus and found that cell-bound virus is highly infectious for T cells. The enhanced infectivity of cell-bound virus was not due to infection of CD4
cells, signaling, or selection of infectious
particles. In contrast, anti-LFA-1 antibody significantly inhibited
cell-bound virus infectivity but only marginally inhibited cell-free
virus infection. Although other cell surface molecules could be
important in virus transmission from cell to cell, our findings are
consistent with other studies that demonstrated the importance of LFA-1
in cell-associated HIV transmission to target cells. Tsunetsugu-Yokota
et al. showed that transmission of dendritic-cell (DC)-associated virus
to T cells was substantially inhibited when LFA-1-ICAM-1 or LFA-3-CD2 interactions were blocked (39). Similarly, Kacani et al.
demonstrated that anti-CD18 antibody inhibited transmission of
non-syncytium-inducing strains of HIV from DCs to monocyte-derived
macrophages (17). In those studies, immature DCs were more
efficient than mature DCs at transferring HIV to monocyte-derived
macrophages. The efficiency of virus transfer correlated with
expression of
2 integrins CD11b, CD11c, and CD18.
In vivo, CD4+ T cells interconvert between a nonadherent
state when in circulation to an adherent cell type when in lymphoid and
other tissues (5). As CD4+ cells circulate
through sites of inflammation, they become adherent and bind to a
variety of antigen-presenting cells (APC) and non-APC. Although the
interaction of CD4+ T cells with non-APC is transient (less
than 30 min), this may allow virus transfer while, in contrast,
antigen-dependent adhesion of cells can occur for hours to days
(1, 5). In cell culture, stimulated T lymphocytes are
capable of binding tightly to non-APC (5). When stimulated T
lymphocytes bind to non-APC, the close proximity of cell membranes is
likely to facilitate a much more efficient transfer of virus from the
CD4
cell to the T cell. In contrast, at low
concentrations of cell-free virus, the probability that a similar
number of cell-free virus particles will bind to CD4+ T
cells is low, due to Brownian motion and electrostatic inhibition (3). In our studies, CD4
cells with bound
virus did not have to be metabolically active since formaldehyde
fixation of the cells did not affect virus transfer. This interaction
is analogous to the ability of formaldehyde-fixed APC to present
antigen to T cells (40). Thus, fixed cells can participate
in cell-cell adhesion. A recent study by Liao et al. demonstrated that
293 cells could bind and transfer HIV to permissive cells
(21). When ICAM was expressed in these cells, the ability to
bind virus was enhanced and, more importantly, the infection of
permissive cells during coculture was substantially increased.
Since DCs are specialized to interact with T cells during antigen
presentation, it is interesting to consider how the transfer of virus
to T cells in our study compares to previous reports of DC transfer of
virus to permissive cells. Several studies compared the efficiency of
infection of DC-bound virus to that of cell-free virus. In those
studies, enhanced infection by DC-bound virus, compared to cell-free
infection, was similar to that observed in our study. For example,
Kacani et al. (17) showed that DC-bound virus infection of
monocytes and monocyte-derived macrophages required 10-fold less virus
than cell-free infection. Similarly, an earlier study by
Tsunetsugu-Yokota et al. (39) demonstrated a 10-fold
increase in virus replication over cell-free infection when T cells
were infected by DC-bound HIV. Similar to our findings, both of those
studies demonstrated that blocking of adhesion interactions during
coculture reduced virus infection. Although the studies cited above
revealed an efficiency of virus transfer to permissive cells similar to
that shown by our studies, there appear to be several unique
differences between DCs and the cells we studied. Thus, DCs express CD4
as well as X4 and R5. In addition, recent studies reported that DCs
bind and capture virus through the DC-specific type C lectin (DC-SIGN)
and internalize virus (12). Further, under some conditions,
DCs become infected with HIV and therefore could cause cell-associated
infection of neighboring cells, which is a mechanism of infection
significantly different from the cell-bound enhancement of infection
observed in our study. Furthermore, in addition to delivering virus, it
is also possible that DCs can stimulate permissive cells to enhance HIV
replication (17, 39).
Interestingly, it appears that the efficiency of virus infection of T
cells depends on the type of cells with bound virus. In our studies,
virus bound to neutrophils and lymphocytes more efficiently infected T
cells than did virus bound to platelets and erythrocytes. This suggests
that some cell types, including nonnucleated erythrocytes and
platelets, have less contact with T cells while other cell types
express relatively higher levels of complementary adhesion and immune
recognition molecules and participate in more interactions with
CD4+ T cells. Therefore, it stands to reason that cells
with tighter cell-cell binding with CD4+ T cells can
transfer virus to T cells more efficiently.
Binding of HIV to CD4
cells could be important during
transmission of HIV infection. During transmission, numerous uninfected cell types could carry bound virus into the new host or cell-free virus
could bind to a variety of CD4
host cells. Additionally,
cell-free virus that is transferred during transmission is more likely
to come into contact with CD4
cells since they are more
predominant. For example, cell-free virus introduced into the
bloodstream of an uninfected subject would most likely bind to
erythrocytes, platelets, and neutrophils since <0.1% of blood cells
are CD4+. Although CD4
cells may be
nonpermissive to HIV infection, our studies suggest that bound virions
remain infectious to CD4+ T cells. Moreover, some
CD4
cell types with bound virus could distribute virus to
sites that contain activated target cells. Another implication of these
findings is that plasma viremia does not accurately represent the total virus load in blood since only cell-free virus is measured. Since cell-bound virus more efficiently infects T cells, this undetected population of virus could represent a potentially important reservoir of virus in vivo.
 |
ACKNOWLEDGMENTS |
This work was supported by grant AI-31812 from the National
Institutes of Health, Bethesda, Md.
We thank Neeta Shenoy for assistance in isolating neutrophils and
Shauna Lasky for help with pilot studies.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Immunology/Microbiology, Rush University, 1653 West Congress Pkwy.,
Chicago, IL 60612. Phone: (312) 942-2083. Fax: (312) 942-2808. E-mail: gspear{at}rush.edu.
 |
REFERENCES |
| 1.
|
Ben-Sasson, S. Z.,
M. F. Lipscomb,
T. F. Tucker, and J. W. Uhr.
1978.
Specific binding of T lymphocytes to macrophages. III. Spontaneous dissociation of T cells from antigen-pulsed macrophages.
J. Immunol.
120:1902-1906[Abstract/Free Full Text].
|
| 2.
|
Carr, J. M.,
H. Hocking,
P. Li, and C. J. Burrell.
1999.
Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes.
Virology
265:319-329[CrossRef][Medline].
|
| 3.
|
Chuck, A. S.,
M. F. Clarke, and B. O. Palsson.
1996.
Retroviral infection is limited by Brownian motion.
Hum. Gene Ther.
7:1527-1534[Medline].
|
| 4.
|
Dimitrov, D. S.,
R. L. Willey,
H. Sato,
L. J. Chang,
R. Blumenthal, and M. A. Martin.
1993.
Quantitation of human immunodeficiency virus type 1 infection kinetics.
J. Virol.
67:2182-2190[Abstract/Free Full Text].
|
| 5.
|
Dustin, M. L., and T. A. Springer.
1991.
Role of lymphocyte adhesion receptors in transient interactions and cell locomotion.
Annu. Rev. Immunol.
9:27-66[CrossRef][Medline].
|
| 6.
|
Finzi, D., and R. F. Silliciano.
1998.
Viral dynamics in HIV-1 infection.
Cell
93:665-671[CrossRef][Medline].
|
| 7.
|
Fiscus, S. A.,
J. D. Folds, and C. M. van der Horst.
1993.
Infectious immune complexes in HIV-1-infected patients.
Viral Immunol.
6:135-141[Medline].
|
| 8.
|
Folks, T. M.,
D. Powell,
M. Lightfoote,
S. Koenig,
A. S. Fauci,
S. Benn,
A. Rabson,
D. Daugherty,
H. E. Gendelman,
M. D. Hoggan, et al.
1986.
Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus.
J. Exp. Med.
164:280-290[Abstract/Free Full Text].
|
| 9.
|
Fortin, J. F.,
R. Cantin,
G. Lamontagne, and M. Tremblay.
1997.
Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity.
J. Virol.
71:3588-3596[Abstract].
|
| 10.
|
Fortin, J. F.,
R. Cantin, and M. J. Tremblay.
1998.
T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1.
J. Virol.
72:2105-2112[Abstract/Free Full Text].
|
| 11.
|
Fujiwara, M.,
R. Tsunoda,
S. Shigeta,
T. Yokota, and M. Baba.
1999.
Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through CD54-CD11a interaction.
J. Virol.
73:3603-3607[Abstract/Free Full Text].
|
| 12.
|
Geijtenbeek, T. B.,
D. S. Kwon,
R. Torensma,
S. J. van Vliet,
G. C. van Duijnhoven,
J. Middel,
I. L. Cornelissen,
H. S. Nottet,
V. N. KewalRamani,
D. R. Littman,
C. G. Figdor, and Y. van Kooyk.
2000.
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.
Cell
5:587-597.
|
| 13.
|
Heath, S. L.,
J. G. Tew,
A. K. Szakal, and G. F. Burton.
1995.
Follicular dendritic cells and human immunodeficiency virus infectivity.
Nature
377:740-744[CrossRef][Medline].
|
| 14.
|
Ibrahim, J.,
P. Griffin,
D. R. Coombe,
C. C. Rider, and W. James.
1999.
Cell-surface heparan sulfate facilitates human immunodeficiency virus type 1 entry into some cell lines but not primary lymphocytes.
Virus Res.
60:159-169[CrossRef][Medline].
|
| 15.
|
Jakubik, J. J.,
M. Saifuddin,
D. M. Takefman, and G. T. Spear.
1999.
B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.
Immunology
96:612-619[CrossRef][Medline].
|
| 16.
|
Jakubik, J. J.,
M. Saifuddin,
D. M. Takefman, and G. T. Spear.
2000.
Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes.
J. Virol.
74:552-555[Abstract/Free Full Text].
|
| 17.
|
Kacani, L.,
I. Frank,
M. Spruth,
M. G. Schwendinger,
B. Müllauer,
G. M. Sprinzl,
F. Steindl, and M. P. Dierich.
1998.
Dendritic cells transmit human immunodeficiency virus type 1 to monocytes and monocyte-derived macrophages.
J. Virol.
72:6671-6677[Abstract/Free Full Text].
|
| 18.
|
Kwok, S.,
M. D. H., J. J. Sninsky,
G. D. Ehrlich,
B. J. Poiesz,
N. L. Dock,
H. J. Alter,
D. Mildvan, and M. H. Grieco.
1989.
Diagnosis of human immunodeficiency virus in seropositive individuals: enzymatic amplification of HIV viral sequences in peripheral blood mononuclear cells.
Marcel Dekker, Inc., New York, N.Y.
|
| 19.
|
Lachgar, A.,
G. Jaureguiberry,
H. Le Buenac,
B. Bizzini,
J. F. Zagury,
J. Rappaport, and D. Zagury.
1998.
Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC).
Biomed. Pharmacother.
52:436-439[CrossRef][Medline].
|
| 20.
|
Lahm, H. W., and S. Stein.
1985.
Characterization of recombinant human interleukin-2 with micromethods.
J. Chromatogr.
326:357-361[CrossRef][Medline].
|
| 21.
|
Liao, Z.,
J. R. Roos, and J. E. K. Hildreth.
2000.
Increase infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4.
AIDS Res. Hum. Retrovir.
16:355-366[CrossRef][Medline].
|
| 22.
|
McDougal, J. S.,
M. Hubbard,
J. K. Nicholson,
B. M. Jones,
R. C. Holman,
J. Roberts,
D. B. Fishbein,
H. W. Jaffe,
J. E. Kaplan,
T. J. Spira, et al.
1985.
Immune complexes in the acquired immunodeficiency syndrome (AIDS): relationship to disease manifestation, risk group, and immunologic defect.
J. Clin. Immunol.
5:130-138[CrossRef][Medline].
|
| 23.
|
Mondor, I.,
S. Ugolini, and Q. J. Sattentau.
1998.
Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.
J. Virol.
72:3623-3634[Abstract/Free Full Text].
|
| 24.
|
Morrow, W. J.,
M. Wharton,
R. B. Stricker, and J. A. Levy.
1986.
Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus.
Clin. Immunol. Immunopathol.
40:515-524[CrossRef][Medline].
|
| 25.
|
Notter, M. F.,
J. F. Leary, and P. C. Balduzzi.
1982.
Adsorption of Rous sarcoma virus to genetically susceptible and resistant chicken cells studied by laser flow cytometry.
J. Virol.
41:958-964[Abstract/Free Full Text].
|
| 26.
|
Ohshiro, Y.,
T. Murakami,
K. Matsuda,
K. Nishioka,
K. Yoshida, and N. Yamamoto.
1996.
Role of cell surface glycosaminoglycans of human T cells in human immunodeficiency virus type-1 (HIV-1) infection.
Microbiol. Immunol.
40:827-835[Medline].
|
| 27.
|
Ou, C. Y.,
S. Kwok,
S. W. Mitchell,
D. H. Mack,
J. J. Sninsky,
J. W. Krebs,
P. Feorino,
D. Warfield, and G. Schochetman.
1988.
DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells.
Science
239:295-297[Abstract/Free Full Text]. (Erratum, 240:240.)
|
| 28.
|
Patel, M.,
M. Yanagishita,
G. Roderiquez,
D. C. Bou-Habib,
T. Oravecz,
V. C. Hascall, and M. A. Norcross.
1993.
Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines.
AIDS Res. Hum. Retrovir.
9:167-174[Medline].
|
| 29.
|
Piraino, F.,
E. R. Krumbiegel, and H. J. Wisniewski.
1967.
Serologic survey of man for avian leukosis virus infection.
J. Immunol.
98:702-706[Abstract/Free Full Text].
|
| 30.
|
Pizzato, M.,
S. A. Marlow,
E. D. Blair, and Y. Takeuchi.
1999.
Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction.
J. Virol.
73:8599-8611[Abstract/Free Full Text].
|
| 31.
|
Ramratnam, B.,
S. Bonhoeffer,
J. Binley,
A. Hurley,
L. Zhang,
J. E. Mittler,
M. Markowitz,
J. P. Moore,
A. S. Perelson, and D. D. Ho.
1999.
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.
Lancet
354:1782-1785[CrossRef][Medline].
|
| 32.
|
Saphire, A. C.,
M. D. Bobardt, and P. A. Gallay.
1999.
Host cyclophilin A mediates HIV-1 attachment to target cells via heparans.
EMBO J.
18:6771-6785[CrossRef][Medline].
|
| 33.
|
Sato, H.,
J. Orenstein,
D. Dimitrov, and M. Martin.
1992.
Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles.
Virology
186:712-724[CrossRef][Medline].
|
| 34.
|
Schlegel, R., and M. Wade.
1983.
Neutralized vesicular stomatitis virus binds to host cells by a different "receptor."
Biochem. Biophys. Res. Commun.
114:774-778[CrossRef][Medline].
|
| 35.
|
Schlegel, R.,
M. C. Willingham, and I. H. Pastan.
1982.
Saturable binding sites for vesicular stomatitis virus on the surface of Vero cells.
J. Virol.
43:871-875[Abstract/Free Full Text].
|
| 36.
|
Sullivan, B. L.,
E. J. Knopoff,
M. Saifuddin,
D. M. Takefman,
M. N. Saarloos,
B. E. Sha, and G. T. Spear.
1996.
Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
J. Immunol.
157:1791-1798[Abstract].
|
| 37.
|
Sullivan, B. L.,
D. M. Takefman, and G. T. Spear.
1998.
Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism.
Virology
248:173-181[CrossRef][Medline].
|
| 38.
|
Takefman, D. M.,
B. L. Sullivan,
B. E. Sha, and G. T. Spear.
1998.
Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis.
Virology
246:370-378[CrossRef][Medline].
|
| 39.
|
Tsunetsugu-Yokota, Y.,
S. Yasuda,
A. Sugimoto,
T. Yagi,
M. Azuma,
H. Yagita,
K. Akagawa, and T. Takemori.
1997.
Efficient virus transmission from dendritic cells to CD4+ T cells in response to antigen depends on close contact through adhesion molecules.
Virology
239:259-268[CrossRef][Medline].
|
| 40.
|
Ziegler, K., and E. R. Unanue.
1981.
Identification of a macrophage antigen-processing event required for I-region-restricted antigen presentation to T lymphocytes.
J. Immunol.
127:1869-1875[Abstract].
|
Journal of Virology, September 2000, p. 8550-8557, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Elbim, C., Monceaux, V., Mueller, Y. M., Lewis, M. G., Francois, S., Diop, O., Akarid, K., Hurtrel, B., Gougerot-Pocidalo, M.-A., Levy, Y., Katsikis, P. D., Estaquier, J.
(2008). Early Divergence in Neutrophil Apoptosis between Pathogenic and Nonpathogenic Simian Immunodeficiency Virus Infections of Nonhuman Primates. J. Immunol.
181: 8613-8623
[Abstract]
[Full Text]
-
Crublet, E., Andrieu, J.-P., Vives, R. R., Lortat-Jacob, H.
(2008). The HIV-1 Envelope Glycoprotein gp120 Features Four Heparan Sulfate Binding Domains, Including the Co-receptor Binding Site. J. Biol. Chem.
283: 15193-15200
[Abstract]
[Full Text]
-
Duval, M., Posner, M. R., Cavacini, L. A.
(2008). A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils. J. Virol.
82: 4671-4674
[Abstract]
[Full Text]
-
Heit, B., Jones, G., Knight, D., Antony, J. M., Gill, M. J., Brown, C., Power, C., Kubes, P.
(2006). HIV and Other Lentiviral Infections Cause Defects in Neutrophil Chemotaxis, Recruitment, and Cell Structure: Immunorestorative Effects of Granulocyte-Macrophage Colony-Stimulating Factor. J. Immunol.
177: 6405-6414
[Abstract]
[Full Text]
-
Chaipan, C., Soilleux, E. J., Simpson, P., Hofmann, H., Gramberg, T., Marzi, A., Geier, M., Stewart, E. A., Eisemann, J., Steinkasserer, A., Suzuki-Inoue, K., Fuller, G. L., Pearce, A. C., Watson, S. P., Hoxie, J. A., Baribaud, F., Pohlmann, S.
(2006). DC-SIGN and CLEC-2 Mediate Human Immunodeficiency Virus Type 1 Capture by Platelets.. J. Virol.
80: 8951-8960
[Abstract]
[Full Text]
-
Zahn, A., Jennings, N., Ouwehand, W. H., Allain, J.-P.
(2006). Hepatitis C virus interacts with human platelet glycoprotein VI.. J. Gen. Virol.
87: 2243-2251
[Abstract]
[Full Text]
-
Gabali, A. M., Anzinger, J. J., Spear, G. T., Thomas, L. L.
(2004). Activation by Inflammatory Stimuli Increases Neutrophil Binding of Human Immunodeficiency Virus Type 1 and Subsequent Infection of Lymphocytes. J. Virol.
78: 10833-10836
[Abstract]
[Full Text]
-
Horakova, E., Gasser, O., Sadallah, S., Inal, J. M., Bourgeois, G., Ziekau, I., Klimkait, T., Schifferli, J. A.
(2004). Complement Mediates the Binding of HIV to Erythrocytes. J. Immunol.
173: 4236-4241
[Abstract]
[Full Text]
-
Trumpfheller, C., Park, C. G., Finke, J., Steinman, R. M., Granelli-Piperno, A.
(2003). Cell type-dependent retention and transmission of HIV-1 by DC-SIGN. Int Immunol
15: 289-298
[Abstract]
[Full Text]
-
Gummuluru, S., KewalRamani, V. N., Emerman, M.
(2002). Dendritic Cell-Mediated Viral Transfer to T Cells Is Required for Human Immunodeficiency Virus Type 1 Persistence in the Face of Rapid Cell Turnover. J. Virol.
76: 10692-10701
[Abstract]
[Full Text]
-
Baribaud, F., Pohlmann, S., Sparwasser, T., Kimata, M. T. Y., Choi, Y.-K., Haggarty, B. S., Ahmad, N., Macfarlan, T., Edwards, T. G., Leslie, G. J., Arnason, J., Reinhart, T. A., Kimata, J. T., Littman, D. R., Hoxie, J. A., Doms, R. W.
(2001). Functional and Antigenic Characterization of Human, Rhesus Macaque, Pigtailed Macaque, and Murine DC-SIGN. J. Virol.
75: 10281-10289
[Abstract]
[Full Text]
-
Pohlmann, S., Leslie, G. J., Edwards, T. G., Macfarlan, T., Reeves, J. D., Hiebenthal-Millow, K., Kirchhoff, F., Baribaud, F., Doms, R. W.
(2001). DC-SIGN Interactions with Human Immunodeficiency Virus: Virus Binding and Transfer Are Dissociable Functions. J. Virol.
75: 10523-10526
[Abstract]
[Full Text]
-
Saphire, A. C. S., Bobardt, M. D., Zhang, Z., David, G., Gallay, P. A.
(2001). Syndecans Serve as Attachment Receptors for Human Immunodeficiency Virus Type 1 on Macrophages. J. Virol.
75: 9187-9200
[Abstract]
[Full Text]